Literature DB >> 8262860

Mechanisms of quinolone resistance in clinical isolates: accumulation of sparfloxacin and of fluoroquinolones of various hydrophobicity, and analysis of membrane composition.

A Denis1, N J Moreau.   

Abstract

The accumulation of sparfloxacin and three other fluoroquinolones of decreasing hydrophobicity, pefloxacin, ofloxacin, and ciprofloxacin, into randomly chosen fluoroquinolone-sensitive and -resistant clinical isolates of bacteria (four Enterobacteriaceae, one Pseudomonas aeruginosa and one Staphylococcus aureus) was measured. There was good correlation between the concentration of drug that inhibited early DNA synthesis in whole cells and the MIC values of the same drug regardless of organism sensitivity or the quinolone. A decrease in permeability in resistant strains compared with sensitive, due to a modification of outer membrane proteins was often involved in resistance. But, in all cases other mutations may also be involved explaining the relatively high level of resistance of the strains. In two resistant strains the DNA gyrase was purified and found to be resistant to inhibition by quinolones. The use of quinolones of differing hydrophobicity emphasized the importance of this property in the uptake of quinolones by bacterial cells, and provided evidence that sparfloxacin used both porin and the self-promoted uptake pathway for it's uptake.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8262860     DOI: 10.1093/jac/32.3.379

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.

Authors:  V Zeller; C Janoir; M D Kitzis; L Gutmann; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium.

Authors:  E Giraud; A Cloeckaert; D Kerboeuf; E Chaslus-Dancla
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Comparative aspects of the diffusion of norfloxacin, cefepime and spermine through the F porin channel of Enterobacter cloacae.

Authors:  J Chevalier; M Malléa; J M Pagès
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

4.  A novel, double mutation in DNA gyrase A of Escherichia coli conferring resistance to quinolone antibiotics.

Authors:  Q C Truong; J C Nguyen Van; D Shlaes; L Gutmann; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Resistance to fluoroquinolones in Escherichia coli isolated from poultry.

Authors:  S Bazile-Pham-Khac; Q C Truong; J P Lafont; L Gutmann; X Y Zhou; M Osman; N J Moreau
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Fluorescence quenching as a tool to investigate quinolone antibiotic interactions with bacterial protein OmpF.

Authors:  Patrícia Neves; Isabel Sousa; Mathias Winterhalter; Paula Gameiro
Journal:  J Membr Biol       Date:  2009-01-16       Impact factor: 1.843

7.  Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus.

Authors:  T Takenouchi; F Tabata; Y Iwata; H Hanzawa; M Sugawara; S Ohya
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

8.  Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.

Authors:  T Kocagöz; C J Hackbarth; I Unsal; E Y Rosenberg; H Nikaido; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.

Authors:  G G Zhanel; J A Karlowsky; M H Saunders; R J Davidson; D J Hoban; R E Hancock; I McLean; L E Nicolle
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 10.  Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.

Authors:  K L Goa; H M Bryson; A Markham
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.